Table 1.

Chronological summary of US Food and Drug Administration approved anti-HER2 treatments in HER2-amplified breast cancer

Year of approval	Cancer stage	Agent	Study name	Chemotherapy
1998 [2]	First-line metastatic	T	-	Pac or AC
1998 [2]	Second-line and third-line metastatic	T	-	None
2006 [1],[15]	Adjuvant	T	B31/N9831/BCIG006	AC → Pac, TCH
2006 [16]	Metastatic	L	-	Capecitabine
2009 [17]	Metastatic	L + AI	TAnDEM	None
2012 [18]	Metastatic	P + T	CLEOPATRA	Docetaxel
2013 [13]	Metastatic	TDM-1	EMILIA	None
2013 [19]	Neoadjuvant	P + T	NeoSphere	FEC → Pac, TCH

AI, aromatase inhibitor; AC, doxorubicin and cyclophosphamide; FEC, fluorouracil, epirubicin, cyclophosphamide, HER, human epidermal growth factor receptor; L, lapatinib; P, pertuzumab; Pac, paclitaxel; T, trastuzumab; TCH, docetaxel, carboplatin and trastuzumab; TDM-1, ado-trastuzumab emtansine.